Nanomedicines improve drug bioavailability, the dose–response relationship, targeting
ability, efficacy and safety compared to conventional freely administered drugs …

Employing the full arsenal of therapeutics to treat brain tumors is limited by the relative
impermeability of the blood–brain and blood–tumor barriers. In physiologic states, the blood …

Background Approximately 20% of all cancer patients will develop brain metastases in their
lifespan. The standard of care for patients with multiple brain metastases is whole-brain …

Focused ultrasound and microbubbles can non-invasively and locally deliver therapeutics
and imaging agents across the blood–brain barrier. Uniform treatment and minimal adverse …

Microbubbles (MBs) combined with focused ultrasound (FUS) has emerged as a promising
noninvasive technique to permeabilize the blood–brain barrier (BBB) for drug delivery into …

Drug delivery to the central nervous system (CNS) has been a major challenge for CNS
tumors due to the impermeability of the blood-brain barrier (BBB). There has been a …

Patients with metastatic breast cancer have high and continually increasing rates of brain
metastases. During the course of the disease, brain metastases can occur in up to 30% of …

Glioblastoma is the most common primary, malignant brain tumor that remains uniformly
lethal in nearly all cases as a result of extreme cellular heterogeneity, treatment resistance …

Introduction Central nervous system (CNS) disorders present major therapeutic challenges
due to the presence of the blood–brain barrier (BBB) and disease heterogeneity. The BBB …

Recent investigations have shown serotonin's stimulatory effect on several types of cancers
and carcinoid tumors. Nowadays there has been a significant increase in interest in 5-HT7 …